| Literature DB >> 28424790 |
Yang Yang1, Xiaodong Qin1, Yingjun Sun1, Guozheng Cong1, Yanmin Li1, Zhidong Zhang1.
Abstract
Porcine circovirus virus type II (PCV2) is the etiology of postweaning multisystemic wasting syndrome (PMWS), porcine dermatitis, nephropathy syndrome (PDNS), and necrotizing pneumonia. Rapid diagnosis tool for detection of PCV2 plays an important role in the disease control and eradication program. Recombinase polymerase amplification (RPA) assays using a real-time fluorescent detection (PCV2 real-time RPA assay) and RPA combined with lateral flow dipstick (PCV2 RPA LFD assay) were developed targeting the PCV2 ORF2 gene. The results showed that the sensitivity of the PCV2 real-time RPA assay was 102 copies per reaction within 20 min at 37°C and the PCV2 RPA LFD assay had a detection limit of 102 copies per reaction in less than 20 min at 37°C. Both assays were highly specific for PCV2, with no cross-reactions with porcine circovirus virus type 1, foot-and-mouth disease virus, pseudorabies virus, porcine parvovirus, porcine reproductive and respiratory syndrome virus, and classical swine fever virus. Therefore, the RPA assays provide a novel alternative for simple, sensitive, and specific identification of PCV2.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28424790 PMCID: PMC5382309 DOI: 10.1155/2017/8403642
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Evaluation of the specificity of PCV2 real-time RPA assay and PCV2 RPA LFD assay.
| Virus family | Virus species | Virus strain | Real-time RPA | RPA LFD | Real-time qPCR |
|---|---|---|---|---|---|
| Circoviridae | PCV2 | NX strain | 6 min | + | 15 (CT) |
| PCV2 | CQ strain | 5.6 min | + | 14 (CT) | |
| PCV1 | JL strain | − | − | − | |
| Arteriviridae | PRRSV | CH-1R | − | − | − |
| Herpesviridae | PRV | Fa | − | − | − |
| Flaviviridae | CSF | C-strain | − | − | − |
| Parvoviridae | PPV | AV30 | − | − | − |
| Picornaviridae | FMDV | FMDV/O/CHA | − | − | − |
+Positive; −negative.
RPA primers and probes designed in this research.
| Name | Sequence (5′ –3′) | Genome location (DQ231511) |
|---|---|---|
| PCV2 RPA Fe1 | ATACCATAACCCAGCCCTTCTCCTACCACTCCCGC | 443–477 |
| PCV2 RPA Fe2 | ATAACCCAGCCCTTCTCCTACCACTCCCGCTACTT | 448–482 |
| PCV2 RPA Fe3 | AAACCTGTCCTAGATTCCACTATTGATTACTTCCA | 490–524 |
| PCV2 RPA Re1 | TTGTATTCCTGGTCGTATATACTGTTTTCGAACGC | 601–635 |
| PCV2 RPA Re2 | ATATTGTATTCCTGGTCGTATATACTGTTTTCGAA | 604–638 |
| PCV2 RPA Re3 | TTACACGGATATTGTATTCCTGGTCGTATATACTG | 612–646 |
| PCV2 RPA Pe | ATTACTTCCAACCAAACAACAAAAGAAATCAGCTG | 515–569 |
| (FAM-dT)G(THF)C(BHQ1-dT)GAGACTACAAACTGC-C3 space | ||
| PCV2 RPA Fn1 | ATACCATAACCCAGCCCTTCTCCTACCACTCCCGC | 443–477 |
| PCV2 RPA Fn2 | ATAACCCAGCCCTTCTCCTACCACTCCCGCTACTT | 448–482 |
| PCV2 RPA Fn3 | AAACCTGTCCTAGATTCCACTATTGATTACTTCCA | 490–524 |
| PCV2 RPA Rn1 | biotin-TTGTATTCCTGGTCGTATATACTGTTTTCGAACGC | 601–635 |
| PCV2 RPA Rn2 | biotin-ATATTGTATTCCTGGTCGTATATACTGTTTTCGAA | 604–638 |
| PCV2 RPA Rn3 | biotin-TTACACGGATATTGTATTCCTGGTCGTATATACTG | 612–646 |
| PCV2 RPA Pn | FAM-TACTTCCAACCAAACAACAAAAGAAATCAGCTGTG | 517–567 |
| -THF-CTGAGACTACAAACT-C3 space |
Figure 1Optimal primers and probe combinations of PCV2 real-time RPA assay. The amplification results of nine different combinations of primers with the probe PCV2 RPA Pe are shown.
Figure 2The sensitivity of PCV2 real-time RPA assay. (a) Fluorescence performance via real-time test using a dilution range of pPCV2/RPA. (b) Reproducibility of the PCV2 real-time RPA assay according to eight test runs. (c) Probit regression analysis was done on data from the eight runs of PCV2 real-time RPA assay.
Figure 4Evaluation of the sensitivity of PCV2 RPA LFD assay. (a) In the lateral flow format (PCV2 RPA LFD) the sensitivity was 102 copies of the standard DNA. (b) Positive PCV2 RPA LFD reaction products (146 bp) could be detected on a stained agarose gel (3%).
Figure 5(a) Specificity test results of PCV2 RPA LFD assay using total DNA extracted from PCV2 virus and other virus. (b) Positive PCV2 RPA LFD reaction products (146 bp) could be detected on a stained agarose gel (3%).
Comparison of PCV2 real-time RPA assay and PCV2 RPA LFD assay with real-time qPCR assay on clinical samples.
| Clinical sample | Real-time RPA | RPA LFD | Real-time qPCR | |||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |
| Spleen | 4 | 12 | 4 | 12 | 4 | 12 |
| Inguinal lymph node | 6 | 19 | 6 | 19 | 6 | 19 |
| Tonsil | 9 | 17 | 9 | 17 | 9 | 17 |
| Lung | 7 | 12 | 7 | 12 | 7 | 12 |
| Serum | 5 | 11 | 5 | 11 | 5 | 11 |
| Total | 31 | 71 | 31 | 71 | 31 | 71 |
The performance of innuPREP MP basic kit on PCV2 positive samples (n = 31) was tested by real-time RPA assay, RPA LFD assay, and real-time qPCR assay, respectively.
| Sample name | Real-time qPCR (CT) | Real-time RPA (min) | RPA LFD |
|---|---|---|---|
| Spleen 1 | 25 | 7 | + |
| Spleen 2 | 27 | 7 | + |
| Spleen 3 | 29 | 7.3 | + |
| Spleen 4 | 30 | 7.6 | + |
| Inguinal lymph node 1 | 28 | 7 | + |
| Inguinal lymph node 2 | 32 | 8.3 | + |
| Inguinal lymph node 3 | 31 | 8 | + |
| Inguinal lymph node 4 | 29 | 7.6 | + |
| Inguinal lymph node 5 | 26 | 6.3 | + |
| Inguinal lymph node 6 | 26 | 6.6 | + |
| Tonsil 1 | 30 | 8 | + |
| Tonsil 2 | 31 | 8.3 | + |
| Tonsil 3 | 25 | 6.3 | + |
| Tonsil 4 | 25 | 6.6 | + |
| Tonsil 5 | 26 | 6.6 | + |
| Tonsil 6 | 27 | 7.3 | + |
| Tonsil 7 | 27 | 7.6 | + |
| Tonsil 8 | 28 | 7.3 | + |
| Tonsil 9 | 24 | 6 | + |
| Lung 1 | 24 | 6.3 | + |
| Lung 2 | 24 | 6.6 | + |
| Lung 3 | 29 | 7 | + |
| Lung 4 | 22 | 6.3 | + |
| Lung 5 | 22 | 6.6 | + |
| Lung 6 | 30 | 8.3 | + |
| Lung 7 | 30 | 8.6 | + |
| Serum 1 | 32 | 9 | + |
| Serum 2 | 32 | 9.3 | + |
| Serum 3 | 27 | 7.6 | + |
| Serum 4 | 29 | 7.6 | + |
| Serum 5 | 25 | 7.3 | + |
Figure 3Optimal detection conditions of PCV2 RPA LFD assay. (a)The assay works in a broad range of temperatures. (b) After 10 min of amplification, the test line is visible on the lateral flow dipstick.